1803274-65-8

Basic information

• Product Name: BAY-1436032
• Synonyms: BAY-1436032
• CAS NO: 1803274-65-8
• Molecular Formula: C26H30F3N3O3
• Molecular Weight: 489.5299096
• Mol File: 1803274-65-8.mol

Chemical Properties

• Boiling Point: 591.2±60.0 °C(Predicted)
• Appearance: /
• Density: 1.30±0.1 g/cm3(Predicted)
• PKA: 4.34±0.10(Predicted)
• CAS DataBase Reference: BAY-1436032(CAS DataBase Reference)
• NIST Chemistry Reference: BAY-1436032(1803274-65-8)
• EPA Substance Registry System: BAY-1436032(1803274-65-8)

Safety Data

• Hazardous Substances Data: 1803274-65-8(Hazardous Substances Data)

Usage

Uses

BAY-1436032, is a novel pan-mutant isocitrate dehydrogenase 1 (IDH1) inhibitor.

Upstream product

• 15901-42-5 (1R,5R)-3,3,5-trimethylcyclohexanamine 
• 907602-44-2 3-(4-fluoro-3-nitrophenyl)propionic acid methyl ester 
• 64285-95-6 1-isothiocyanato-4-(trifluoromethoxy)benzene 

Relevant articles and documents

INHIBITOR OF THE MUTATED ISOCITRATE DEHYDROGENASE IDH1 R132H

The present invention relates to the adduct (2E)-but-2-enedioic acid - 3-(2-{[4- (trifluoromethoxy)phenyl]amino}-1-[(1R,5R)-3,3,5-trimethylcyclohexyl]-1H-benzimidazol- -yl)propanoic acid (1:4), methods for preparing this adduct, pharmaceutical compositions comprising this adduct and also the use of this adduct for preparing a medicament for the treatment of a disease.

METHOD FOR PREPARING SUBSTITUTED 3-(2-ANILINO-1-CYCLOHEXYL-1H-BENZIMIDAZOL-5-YL)PROPANOIC ACID DERIVATIVES

The present invention relates to a method for preparing substituted 3-(2-anilino-1-cyclohexyl-1H-benzimidazol-5-yl)propanoic acid derivatives of the general formula (I) in which R1 represents a hydrogen atom or R1 represents a group selected from the series of C1-C3-alkyl-, C1-C3-alkoxy-, C1-C3-haloalkyl- and C1-C3-haloalkoxy-, R2 represents a hydrogen atom or a C1-C3-alkyl group, R3 represents a hydrogen atom or a C1-C3-alkyl group, R4 represents a cyclohexyl group, which is optionally singly or multiply substituted by a C1-C3-alkyl group, and R5 represents a hydrogen atom or a C1-C6-alkyl group; and also intermediates which may be used to prepare substituted 3-(2-anilino-1- cyclohexyl-1H-benzimidazol-5-yl)propanoic acid derivatives. The present invention also relates to a crystalline form of 3-(2-{[4-(trifluoromethoxy)phenyl]amino}-1-[(1R,5R)-3,3,5- trimethylcyclohexyl]-1H-benzimidazol-5-yl)propanoic acid, pharmaceutical compositions comprising this crystalline form, and also the use of this crystalline form for preparing a medicament for the treatment of a disease.

FUSED IMIDAZOLES AS MIDH1 INHIBITORS

The present invention relates to compounds of general formula (I) : in which R1, R2, R3, R4, R6, R7, R8, R9, R10, R11, R12, R13/

BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS

The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.